Melatonin Dependence and Menopausal Insomnia: A Rational Examination of the Evidence

What the Research Actually Shows About Dependence, Tolerance, and Long-Term Use

Introduction: A Question That Deserves a Precise Answer

Melatonin is among the most widely used sleep aids in the United States. A 2022 Sleep Foundation study found that 27.4% of American adults take melatonin. For women navigating the menopausal transition — a period when sleep disruption is both common and consequential — melatonin is often the first over-the-counter option they encounter.

The question this article addresses is specific: Does melatonin use for menopausal insomnia create dependence?

This is not a rhetorical question. It deserves a precise answer, and the precise answer is more nuanced than either the marketing language of supplement companies or the vague warnings of cautious clinicians typically convey. The evidence suggests that physiological dependence on melatonin — in the sense of the body ceasing to produce its own melatonin or requiring escalating doses to achieve the same effect — is unlikely based on current research. However, the picture becomes more complicated when we consider long-term safety data, regulatory gaps, and the specific context of menopausal sleep disturbance.

This article examines what the research actually shows. It does not recommend melatonin. It does not recommend against it. It examines the evidence.

Part 1: What “Dependence” Actually Means in This Context

1.1 Physiological Dependence vs. Psychological Dependence

Before examining the evidence, it is necessary to distinguish between different meanings of “dependence.”

Physiological dependence refers to a state in which the body adapts to a substance such that stopping it produces withdrawal symptoms or physiological disruption. Classic examples include benzodiazepines and opioids.

Tolerance refers to a state in which the same dose produces diminishing effects over time, requiring escalation to achieve the original effect.

Psychological dependence refers to a reliance on a substance for a sense of security or routine, without a clear physiological withdrawal syndrome.

When people ask whether melatonin is “addictive” or “habit-forming,” they are usually asking about physiological dependence or tolerance. The research on melatonin speaks most directly to these questions.

1.2 What the Research Says About Physiological Dependence

The most commonly cited concern about melatonin supplementation is that it might suppress the body‘s natural production of melatonin through a negative feedback mechanism, similar to how exogenous steroids can suppress endogenous steroid production.

The research does not support this concern.

A review published in Nutrients states that “melatonin supplementation is not known to cause a classical feedback phenomenon, meaning that administration of the supplement should not result in tolerance or pineal atrophy”. The review notes that this theoretically means melatonin can be taken indefinitely, though it also acknowledges that this must be confirmed through further clinical study.

The Mayo Clinic similarly states that “unlike many sleep medicines, with melatonin, you are unlikely to become dependent on it or see reduced effectiveness over time”.

A clinical review published through the National Institutes of Health states: “No evidence suggests that patients develop tolerance to melatonin”.

A long-term open-label study of prolonged-release melatonin (PRM) followed patients for up to 52 weeks. During the withdrawal period, the researchers assessed withdrawal symptoms using a somatic symptom checklist and measured urinary 6-sulphatoxymelatonin (6SMT) levels — a reliable measure of endogenous melatonin production. The study found no evidence of physiological withdrawal or suppression of endogenous production.

1.3 The Receptor Sensitivity Caveat

However, the picture is not entirely uncomplicated. One source notes a potential concern that is distinct from classical dependence: “high-dose long-term use of melatonin could potentially reduce sensitivity of receptor sites and create a need for higher doses and even a dependence on exogenous melatonin. The caveat is that there may be a threshold in reducing sensitivity once receptor sites are saturated”.

This is a theoretical concern rather than an established finding. The same source also notes that melatonin from supplementation does not appear to impact endogenous production, based on three decades of research including high-dose studies in cancer patients.

The distinction matters: even if receptor sensitivity changes at high doses, this is not the same as the body ceasing to produce melatonin or the user experiencing withdrawal symptoms when stopping.

Part 2: The Regulatory Gap — Why “Dependence” Is Not the Only Concern

2.1 The Supplement Problem

Melatonin is classified as a dietary supplement in the United States, not as a pharmaceutical drug. This classification has significant consequences.

The FDA does not approve dietary supplements or their labeling before they are sold to consumers. It does not test supplements for content or purity prior to market entry. The agency inspects manufacturing facilities and reviews adverse event reports, but it does not conduct pre-market safety or efficacy reviews for supplements.

A study cited by multiple sources found that 88% of melatonin products tested were inaccurately labeled. Actual amounts of melatonin ranged from 74% to 347% of the labeled quantity. Three products out of 25 contained the advertised amount. One product contained no melatonin at all but instead contained 31 mg of CBD.

This means that when a woman takes a melatonin supplement, she may not be receiving what the label claims. She may be receiving substantially more or less than the stated dose. She may be receiving other substances entirely.

2.2 The Implications for “Dependence”

This regulatory gap complicates the dependence question in a specific way. If a woman experiences difficulty stopping melatonin after long-term use, the cause may not be physiological dependence on melatonin itself. It may be that she has been taking an inconsistent or higher dose than she believes, or that she has developed a psychological reliance on the ritual of taking a supplement before bed.

The distinction matters for how the problem is addressed. If the issue is physiological, it requires a clinical approach. If the issue is psychological, it requires a behavioral approach.

2.3 The Pediatric Data as a Cautionary Context

While this article focuses on menopausal insomnia, the pediatric melatonin data provides a relevant context for understanding the regulatory landscape.

The American Academy of Sleep Medicine reports that accidental ingestions of melatonin in children reported to poison control centers increased by 530% between 2012 and 2021. Pediatric ingestions resulting in emergency department visits increased by 421% between 2009 and 2020.

A recent analysis cited by the NIH reports that annual pediatric melatonin overdose cases increased from 8,000 in 2012 to more than 52,000 in 2021, with 15% of children requiring hospitalization.

These figures do not speak directly to adult dependence. But they illustrate the consequences of a regulatory framework in which a hormonally active substance is sold without the controls applied to pharmaceutical drugs.

Part 3: The Menopausal Context — Why This Population Deserves Specific Attention

3.1 The Particular Vulnerability of Menopausal Women

Menopausal women are a population that deserves specific attention in discussions of melatonin use.

The Menopause Society notes that sleep disturbance is one of the most common symptoms of the menopausal transition, with prevalence estimates ranging from 20% to 60% among perimenopausal and postmenopausal women. Nocturnal hot flashes are a common contributor to sleep disruption, and the relationship between vasomotor symptoms and sleep is complex and bidirectional.

This means that menopausal women are both more likely to experience sleep disturbance and more likely to seek solutions — including over-the-counter supplements like melatonin.

3.2 What the Clinical Guidelines Say About Melatonin

The Menopause Society‘s clinical guidance is notably restrained on the subject of melatonin. The organization states: “Data are limited on melatonin and dietary supplements for menopause-related sleep disturbance”.

This is a significant statement. It does not say melatonin is ineffective. It says the data are limited. For a population experiencing a specific type of sleep disturbance with a specific physiological context, the evidence base for melatonin specifically is insufficient to support strong recommendations.

The guidance also notes that “structured treatment involving CBTi is effective in treating sleep interruption related to VMS and can be delivered in person or remotely by a trained clinician or through web- or app-based algorithms”.

This reflects the broader clinical consensus that behavioral approaches have stronger evidence for menopausal sleep disturbance than over-the-counter supplements.

3.3 The Long-Term Cardiovascular Signal

A preliminary observational study presented at the American Heart Association’s Scientific Sessions 2025 raised a signal that deserves attention, though it requires cautious interpretation.

The study examined 130,828 adults with insomnia, half of whom were prescribed melatonin for at least 12 months. Over a 5-year follow-up period, incident heart failure occurred in 4.6% of melatonin users compared with 2.7% of controls (hazard ratio 1.89). Hospitalization for heart failure was 19% in the melatonin group compared with 6.6% in controls. All-cause mortality was 7.8% in the melatonin group compared with 4.3% in controls.

The study has significant limitations. It is observational, not randomized. It has not been peer-reviewed. It relies on prescription data, which may not capture over-the-counter use. The researchers themselves acknowledged that the findings do not show causation and that short-term use did not appear to raise cardiac risks.

However, the signal is notable because it challenges the assumption that melatonin is entirely benign for long-term use. The study’s lead author stated: “Long-term nightly use may not be as risk-free as we assumed”.

Part 4: What the Evidence Does and Does Not Support

4.1 What the Evidence Supports

Based on the current research:

Physiological dependence on melatonin is unlikely. The evidence does not support the concern that melatonin supplementation suppresses endogenous production or that users develop tolerance requiring dose escalation.

Withdrawal symptoms are not well documented. The long-term study of prolonged-release melatonin found no evidence of withdrawal symptoms or suppression of endogenous production after 26 or 52 weeks of use. The NHS states that “if you take it as prescribed, you’re unlikely to become addicted to it”.

Short-term use appears relatively safe for most people. The Mayo Clinic describes melatonin as “generally safe for short-term use,” with the most common side effects being headache, dizziness, nausea, and daytime drowsiness.

4.2 What the Evidence Does Not Support

The evidence does not support the assumption that melatonin is entirely risk-free for long-term use. The NIH notes that “impaired glucose tolerance has been reported in some cases”. The Mayo Clinic notes that melatonin can interact with medications including blood thinners, anticonvulsants, birth control, blood pressure medications, diabetes medications, and immunosuppressants.

The evidence does not support the assumption that melatonin is appropriate as a first-line or sole intervention. The Mayo Clinic states: “As with any supplement, avoid using melatonin as the first or only solution for sleep issues such as insomnia. It’s best to combine melatonin with lifestyle choices that support overall health”.

The evidence does not support the assumption that melatonin is specifically effective for menopausal sleep disturbance. The Menopause Society states that data are limited, and that CBTi has stronger evidence for this population.

The evidence does not support the assumption that the melatonin you buy is what the label says. The regulatory gap means that content and purity are not guaranteed.

4.3 The Psychological Dependence Question

The research does not speak directly to psychological dependence on melatonin. However, the structure of the product — a nightly pill taken before bed — may create a behavioral reliance that is distinct from physiological dependence.

A woman who has taken melatonin every night for months or years may find it difficult to sleep without it, not because her body has become dependent on the exogenous hormone, but because the ritual of taking the pill has become a conditioned cue for sleep. Removing the pill disrupts the cue.

This is not a reason to avoid melatonin. But it is a reason to be thoughtful about how it is used and whether it is being used as part of a broader sleep strategy or as a substitute for one.

Part 5: What This Means for Women Considering Melatonin

This article does not recommend a specific approach. It presents the evidence as it stands.

For short-term use, melatonin appears relatively safe for most people. The evidence does not support concerns about physiological dependence or tolerance.

For long-term use, the picture is less clear. The cardiovascular signal from the 2025 observational study, while preliminary, suggests that long-term nightly use deserves more scrutiny. The Menopause Society‘s statement that data are limited for menopause-related sleep disturbance is relevant here.

The regulatory gap is a real concern. What you buy may not be what the label says. Third-party testing and United States Pharmacopeia (USP) verification can provide some assurance, but they are not required.

Melatonin is not the only option, and the evidence does not support it as the first-line option for menopausal sleep disturbance. The clinical guidance supports CBTi as the first-line treatment for menopause-related sleep interruption. NICE in the UK has recommended menopause-specific CBT for sleep problems associated with menopause.

If you are taking melatonin and want to stop, the evidence does not suggest a need for tapering. The NHS advises asking a doctor or pharmacist for advice about stopping if you have been taking it for a long time, but the research does not indicate a withdrawal syndrome.

Conclusion: A Precise Answer to an Imprecise Question

The question “Is melatonin addictive?” or “Does melatonin cause dependence?” is often asked in a way that conflates several distinct concerns. The evidence suggests:

• Physiological dependence: Unlikely based on current research.

• Tolerance: Not supported by the evidence.

• Withdrawal symptoms: Not documented in long-term studies.

• Psychological dependence: Not well studied, but plausible given the nightly ritual structure.

• Long-term safety: Less clear than short-term safety, with emerging signals that warrant attention.

• Product quality: A real concern given the regulatory gap.

For menopausal women specifically, the evidence for melatonin is limited, and the clinical guidance points toward behavioral approaches as having stronger support.

The most rational position is not that melatonin is dangerous or that it is safe. It is that melatonin is a hormonally active substance sold under a regulatory framework that does not guarantee content or purity, with evidence supporting short-term safety but less clarity on long-term effects, and with stronger evidence for other approaches in the specific context of menopausal sleep disturbance.

That is the precise answer. It is not a satisfying one, but it is what the evidence supports.

COZHOM — Revere the Night.